Rocacetrapib - Chong Kun Dang Pharmaceutical
Alternative Names: CKD-519Latest Information Update: 05 Mar 2021
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class Antihyperlipidaemics; Cyclohexenes; Halogenated hydrocarbons; Oxazolidinones; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 05 Mar 2021 Discontinued - Phase-II for Dyslipidaemias (Combination therapy) in Australia (PO) (Chong Kun Dang Pharmaceutical pipeline, March 2021)
- 05 Mar 2021 Discontinued - Phase-II for Dyslipidaemias in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, March 2021)
- 05 Mar 2021 Discontinued - Phase-II for Dyslipidaemias in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, March 2021)